Extracellular matrix remodeling in heart failure: A role for de novo angiotensin II generation

Circulation

Volumn 96, Issue 11, 1997, Pages 4065-4082

  Weber, Karl T ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

Angiotensin; Collagen; Diastole; Heart failure remodeling

Indexed keywords

ANGIOTENSIN;

COLLAGEN METABOLISM; EXTRACELLULAR MATRIX; HEALING; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TISSUE REPAIR;

EID: 0030657676     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.11.4065     Document Type: Review

References (277)

1. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
2. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327: 685-691.
3. Cotran RS, Kumar V, Robbins SL. Robbins Pathologic Basis of Disease. 4th ed. Philadelphia, Pa: WB Saunders: 1989.
4. Beltrami CA, Finate N, Rocco M, Feruglio GA, Puricelli C, Cigola E, Quaini F, Sonnenblick EH, Olivetti G, Anversa P. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation. 1994;89:151-163.
5. Doering CW, Jalil JE, Janicki JS, Pick R, Aghili S, Abrahams C. Weber KT, Collagen network remodeling and diastolic stiffness of the rat left ventricle with pressure overload hypertrophy. Cardiovasc Res. 1988;22:686-695.
6. Jalil JE, Doering CW, Janicki JS, Pick R, Shroff SG, Weber KT. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res. 1989;64:1041-1050.
7. Dixon IMC, Ju H, Jassal DS, Peterson DJ. Effect of ramipril and losartan on collagen expression in right and left heart after myocardial infarction. Mol Cell Biochem. 1996;165:31-45.
8. Averill DB, Ferrario CM, Tarazi RC, Sen S, Bajbus R. Cardiac performance in rats with renal hypertension. Circ Res. 1976;38:280-288.
9. Bing OHL, Matsushita S, Fanburg BL, Levine HJ. Mechanical properties of rat cardiac muscle during experimental hypertrophy. Circ Res. 1971;28:233-245.
10. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res. 1993;27:341-348.
11. Weber KT, Anversa P, Armstrong PW, Bauer JH, Brilla CG, Burnett JC, Cruickshank JM, Devereux RB, Giles TD, Korsgaard N, Leier CV, Mendelsohn FAO, Motz WH, Mulvaney MJ. Remodeling and reparation of the cardiovascular system. J Am Coll Cordial. 1992;20:3-16.
12. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation. 1991;83:1771-1779.
13. Pouleur H, Rousseau MF, van Eyll C, Stoieru L, Hayashidi W, Udelson JA, Dolan N, Kinan D, Gallagher P, Ahn S, Benedict CR, Yusuf S, Konstam M, for the SOLVD Investigators. Effects of long-term enalapril therapy on left ventricular diastolic properties in patients with depressed ejection fraction.. Circulation. 1993;88:481-491.
14. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
15. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: flbrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
16. Robert V, Van Thiem N, Cheav SL, Mouas C, Swynghedauw B, Delcayre C. Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension. 1994;24:30-36.
17. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest. 1994;93:2578-2583.
18. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol. 1995;269:E657-E662.
19. Sun Y, Ramires FJA, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion, Cardiovasc Res. 1997;35:138-147.
20. Wollert KC, Studer R, von Bülow B, Drexler H. Survival after myocardial infarction in the rat: role of tissue angiotenisinconverting enzyme inhibition. Circulation. 1994;90:2457-2467.
21. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 1990;82:1730-1736.
22. Strain JE, Grose RM, Factor SM, Fisher JD. Results of endomyocardial biopsy in patients with spontaneous ventricular tachycardia but without apparent structural heart disease. Circulation. 1983;68:1171-1181.
23. Messerli FH, Grodzicki T. Hypertension, left ventricular hypertrophy, ventricular arrhythmias and sudden death. Eur Heart J. 1992;13(suppl D):66-69.
24. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril OB mortality and morbidity in patients with left ventricular dysfunction after myocardsal infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med., 1992;327:669-677.
25. Rouleau JL, de Champlain J, Klein M, Bichet D, Moyé L, Packer M, Dagenais GR, Sussex B, Arnold JM, Sestier F, Parker JO, McEwan P, Bernstein V, Cuddy TE, Lamas G, Gottlieb SS, McCans J, Nadeau C, Delage F, Hamm P, Pfeffer MA. Activation of neurohormonal systems in postinfarction left ventricular hypertrophy. J Am Coll Cardiol. 1993;22:390-398.
26. Johnston CI. Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. Hypertension. 1994;23:258-268.
27. Ehlers MRW, Riordan JF. Angiotensin-converting enzyme: new concepts concerning its biological role. Biochemistry. 1989;28:5311-5318.
28. Studer R, Reinecke H, Müller B, Holte J, Just H, Drexler H. Increased angiotensin-I converting enzyme gene expression in the failing human heart: quantification by competitive RNA polymerase chain reaction. J Clin Invest. 1994;94:301-310.
29. Hokimoto S, Yasue H, Fujimoto K, Sakata R, Miyamoto E. Increased angiotensin converting enzyme activity in left ventricular aneurysm of patients after myocardial infarction. Cardiovasc Res. 1995;29:664-669.
30. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissuespecific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res. 1991;69:475-482.
31. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy: effects on coronary resistance, contractility, and relaxation. J Clin Invest. 1990;86:1913-1920.
32. Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN, Drexler H. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation. 1994;89:2273-2282.
33. Sun Y, Cleutjens JPM, Diaz-Arias AA, Weber KT. Cardiac angiotensin converting enzyme and myocardial fibrosis in the rat. Cardiovasc Res. 1994;28:1423-1432.
34. Ou R, Sun Y, Ganjam VK, Weber KT. In situ production of angiotensin II by fibrosed rat pericardium. J Mol Cell Cardiol. 1996;28:1319-1327.
35. Sappino AP, Schürch W, Gabbiani G, Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. Lab Invest. 1990;63:144-161.
36. Skalli O, Schürch W, Seemayer T, Lagacé R, Montandon D, Pittet B, Gabbiani G. Myofibroblasts from diverse pathologic settings are heterogeneous in their content of actin isoforms and intermediate filament proteins. Lab Invest. 1989;60:275-285.
37. Meggs LG, Coupet J, Huang H, Cheng W, Li P, Capasso JM, Homcy CJ, Anversa P. Regulation of angiotensin II receptors on ventricular myocytes after myocardial infarction in rats. Circ Res. 1993;72:1149-1162.
38. Kajstura J, Cigola E, Malhotra A, Li P, Cheng W, Meggs LG, Anversa P. Angiotensio II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol. 1997;29:859-870.
39. Yamada T, Horiuchi M, Dzau VJ, Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci U S A. 1996;93:156-160.
40. Klickstein LB, Kaempfer CE, Wintroub BU. The granulocyte-angiotensin system: angiotensin I-converting activity of cathepsin G. J Biol Chem. 1982;257:15042-15046.
41. Weber KT, Sun Y, Katwa LC, Cleutjens JPM. Connective tissue: a metabolic entity? J Mol Cell Cardiol. 1995:27:107-120.
42. Killip T III, Kimball JT. Treatment of myocardial infarction in a coronary care unit: a two year experiment with 250 patients. Am J Cardiol 1967;20:457-464.
43. Weber KT, Janicki JS, Russell RO, Rackley CE. identification of high risk subsets of acote myocardlal infarction. Am J Cardiol. 1978;41:197-203.
44. Forrester JS, Diamond G, McHugh TJ, Swan HJ. Filling pressures in the right and left sides of the heart in acute myocardial infarction: a reappraisal of central-venous-pressure monitoring. N Engl J Med. 1971:285:190-193.
45. Cohn JN, Rector TS. Prognosis of congestive heart failure and predictors of mortality. Am J Cardiol. 1988:62:25A-30A.
46. Xie G-Y, Berk MR, Smith MD, Gurlcy JC, DeMaria AN. Prognostic value of Doppler transmitral flow patterns in patients with congestive heart failure. J Am Coll Cardiol. 1994;24:132-139.
47. Pinamonti B, Di Lenarda A, Sinagra G, Camerini F, and the Heart Muscle Disease Study Group. Restrictive left ventricular filling pattern in dilated cardiomyopathy assessed by Doppler echocardiography: clinicall echocardiographic and hemodynamic correlations and prognostic implications. J Am Coll Cordiol. 1993;22:808-815.
48. Weber KT, Janicki JS. The dynamics of ventricular contraction: force, length, and shortening. Fed Proc. 1980;39:188-195.
49. Grossman W. Diastolic dysfunction in congestive heart failure. N Engl J Med. 1991;325:1557-1564.
50. Yu CM, Sanderson JE, Chan S, Yeung L, Hung YT, Woo KS. Right ventricular diastolic dysfunction in heart failure. Circulation, 1996;93:1509-1514.
51. Weber KT. Cardiopulmonary exercise testing and the evaluation of systolic dysfunction. In: Wasserman K, ed. Exercise Gas Exchange in Heart Disease. Armonk, NY: Futura; 1996:55-62.
52. Kitzman DW, Higginbotham MB, Cobb FR, Sheikh KH, Sullivan MJ. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the FrankStarling mechanism. J Am Coll Cardiol. 1991;17:1065-1072.
53. Weber KT, Janicki JS. Lactate production during maximal and submaximal exercise in patients with chronic heart failure, J Am Coll Cordial. 1985;6:717-724.
54. Wilson JR., Ferraro N. Exercise intolerance in patients with chronic left heart failure: relation to oxygen transport and ventilatory abnormalities. Am J Cordial 1983;51:1358-1363.
55. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang C, Kubo SH, Rudin-Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-1729.
56. Villarreal D, Freeman RH, Johnson RA. Neurohormonal modulators and sodium balance in experimental heart failure. Am J Physiol. 1993;264:H1187-H1193.
57. Weber KT, Villarreal D. Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993:71 (suppl A): 3A-11A.
58. Bing OHL, Fanburg BL, Brooks WW, Matsushita S, The effect of the lathyrogen β-amino proprionitrile (BAPN) on the mechanical properties of experimentally hypertrophied rat cardiac muscle. Circ Res. 1978;43:632-637.
59. Thiedemann KU, Holubarsch C, Medugorac I, Jacob R. Connective tissue content and myocardial stiffness in pressure overload hypertrophy: a combined study of morphologic, morphometric, biochemical and mechanical parameters. Basic Res Cardiol. 1983;78:140-155.
60. Hess OM, Schneider J, Koch R, Bamert C, Grimm J, Krayenbuehl HP, Diastolic function and myocardial structure in patients with myocardial hypertrophy: special reference to normalized viscoelastic data. Circulation. 1981;63:360-371.
61. Conrad CH, Brooks WW, Hayes JA, Sen S, Robinson KG, Bing OHL, Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. Circulation. 1995;91:161-170.
62. Litwin SE, Litwin CM, Raya TE, Warner AL, Goldman S. Contractility and stiffness of noninfarcted myocardium after coronary ligatton in rats: effects of chronic angioteosin converting enzyme inhibition. Circulation. 1991;83:1028-1037.
63. Pelouch V, Dixon IMC, Golfman L, Beamish RE, Dhalla NS. Role of extracellular matrix proteins in heart function. Mol Cell Biochem. 1993;129:101-120.
64. Smits JFM, van Krimpen C, Schoemaker RG, Cleutjens JPM. Daemen MJAP. Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J Cardiovasc Pharmacol. 1992;20:772-778.
65. Pfeffer JM, Pfeffer MA, Fishbein MC, Frochlich ED. Cardiac function and morphology with aging in the spontaneously hypertensive rat. Am J Physiol. 1979:6:H461-H468.
66. Boluyt MO, O'Neill L, Meredith AL, Bing OHL, Brooks WW, Conrad CH, Crow MT, Lakatta EG. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure: marked upregulation of genes encoding extracellular matrix components, Circ Res. 1994;75:23-32.
67. Bing OHL, Sen S, Conrad CH. Brooks WW. Myocardial function structure and collagen in the spontaneously hypertensive rat: progression from compensated hypertrophy to haemodynamic impairment. Eur Heart J. 1984;51 (suppl F):43-52.
68. Iwai N, Shimoike H, Kinoshita M. Genes up-regulated in hypertrophied ventricle. Biochem Biophys Res Commun. 1995;209:527-534.
69. Booz GW. Baker KM. Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc Res. 1995;30:537-543.
70. Sharma HS, van Heugten HAA, Goedbloed MA, Verdouw PD, Lamers JMJ. Angiotensin II induced expression of transcription factors precedes increase in transforming growth factor-β1 mRNA in neonatal cardiac fibroblasts. Biochem Biophys Res Commun. 1994;205:105-112.
71. Puri PL, Avantaggiati ML, Burgio VL, Chirillo P, Collepardo D, Natoli G, Balsano C, Levrero M. Reactive oxygen intermediates angiotensin II-induced c-Jun. c-Fos heterodimer DNA binding activity and proliferative hypertrophic responses in myogenic cells, J Biol Chem. 1995;270:22129-22134.
72. Crabos M, Roth M, Hahn AWA, Erne P. Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. J Clin Invest. 1994;93:2372-2378.
73. Reddy HK, Campbell SE, Janicki JS, Zhou G, Weber KT. Coronary microvascular fluid flux and permeability: influence of angiotensin II, aldosterone and acute arterial hypertension. J Lab Clin Med. 1993;121:510-521.
74. Sigusch HH, Ou R, Katwa LC, Campbell SE, Ganjam VK, Reddy HK, Weber KT. Angiotensin-II-induced increase in transcoronary protein clearance: role of hypertension vs. nitric oxide or cyclooxygenase products. Cardiovasc Res. 1995;30:291-298.
75. Michael LH, Hunt JR, Lewis RM, Entman ML. Myocardial ischemia: platelet and thromboxane concentrations in cardiac lymph and the effects of ibuprofen and prostacyclin. Circ Res. 1986;59:49-55.
76. Noda K, Sasaguri M, Ideishi M, Ikeda M, Arakawa K. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc Res. 1993;27:334-340.
77. Hashimoto K, Hirose M, Furukawa K, Hayakawa H, Kimura E. Changes in hemodynamics and bradykinin concentration in coronary sinus blood in experimental coronary artery occlusion. Jpn Heart J. 1977;18:679-689.
78. Bissell MJ, Hall HG, Parry G. How does the extracellular matrix direct gene expression? J Theor Biol. 1982;99:31-68.
79. Volders PGA, Willems IEMG, Cleutjens JPM, Arends J-W, Havenith MG, Daemen MJAP. Interstitial collagen is increased in the non-infarcted human myocardium after myocardial infarction. J Mol Cell Cardiol. 1993;25:1317-1323.
80. van Krimpen C, Smits JFM, Cleutjens JPM, Debets JJ, Schoemaker RG, Struyker-Boudier HA, Bosman FT, Daemen MJ. DNA synthesis in the non-infarcted cardiac interstitium after left coronary artery ligation in the rat heart: effects of captopril. J Mol Cell Cardiol. 1991;23:1245-1253.
81. Sekita S, Katagiri T, Sasai Y, Takeda K. Studies on collagen in the experimental myocardial infarction. Jpn Circ J. 1985;49:171-178.
82. Cleutjens JPM, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol. 1995;27:1281-1292.
83. Knowlton AA, Connelly CM, Romo GM, Mamuya W, Apstein CS, Brecher P, Rapid expression of fibronectin in the rabbit heart after myocardial infarction with and without reperfusion. J Clin Invest. 1992;89:1060-1068.
84. Cleutjens JPM, Verluyten MJA, Smits JFM, Daemen MJAP. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol. 1995;147:325-338.
85. Willems IEMG, Havenith MG, De Mey JGR, Daemen MJAP. The α-smooth muscle actin-positive cells in healing human myocardial scars. Am J Pathol. 1994;145:868-875.
86. Sun Y, Weber KT. Angiotensin converting enzyme and myofibroblasts during tissue repair in the rat heart. J Mol Cell Cardiol. 1996;28:851-858.
87. Hanatani A, Yoshiyama M, Kim S, Omura T, Toda I, Akioka K, Teragaki M, Takeuchi K, Iwao H, Takeda T. Inhibition by angiotensin II type 1 receptor antagonist of cardiac phenotypic modulation after myocardial infarction. J Mol Cell Cardiol. 1995;27:1905-1914.
88. Whittaker P. Unravelling the mysteries of collagen and cicatrix after myocardial infarction. Cardiovasc Res. 1996;31:19-27.
89. Jugdutt BI, Amy RWM. Healing after myocardial infarction in the dog: changes in infarct hydroxyproline and topography. J Am Coll Cardiol. 1986;7:91-102.
90. McCormick RJ, Musch TI, Bergman BC, Thomas DP. Regional differences in LV collagen accumulation and mature cross-linking after myocardial Infarction in rats. Am J Physiol. 1994;266:H354-H359.
91. Pelouch V, Dixon IMC, Sethi R, Dhalla NS. Alteration of collagenous protein profile in congestive heart failure secondary to myocardial infarction, Mol Cell Biochem. 1993;129:121-131.
92. McCulloch CAG, Bordin S, Role of fibrohlast subpopulations in periodontal physiology and pathology. J Periodont Res. 1991;26:144-154.
93. Vracko R, Thorning D. Contractile cells in rat myocardial scar tissue. Lab Invest. 1991;65:214-227.
94. Campbell SE, Janicki JS, Weber KT. Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. J Mol Cell Curdiol. 1995;27:1545-1560.
95. Leslie KO, Taatjes DJ, Schwarz , J, vonTurkovich M, Low RB. Cardiac myofibroblasts express alpha smooth muscle actin during right ventricular pressure overload in the rabbit. Am J Pathol. 1991;139:207-216.
96. Bishop JE, Rhodes S, Laurent GJ, Low RB, Stirewalt WS. Increased collagen synthesis and decreased collagen degradation in right ventricular hypertrophy induced by pressure overload. Cardiovasc Res. 1994;28:1581-1585.
97. Majno G. The story of the myofibroblasts. Am .J Surg Pathol. 1979;3:535-542.
98. Gabbiani G, Hirschel BJ, Ryan GB, Statkov PR, Majno G. Granulation tissue as a contractile organ: a study of structure and function. J Exp Med. 1972;135:719-734.
99. Desmoulière A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor- β1 induces α-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol. 1993;122:103-111.
100. Thompson NL, Bazoberry F, Speir EH, Casscells W, Ferrans VJ, Flanders KC, Kondaiah P, Geiser AG, Sporn MB. Transforming growth factor beta-1 in acute myocardial infarction in rats. Growth Factors. 1988;l:91-99.
101. Casscells W, Bazoberry F, Speir E, Thompson N, Flanders K, Kondaiah P, Ferrans VJ, Epstein SE, Sporn M. Transforming growth factor-β1 in normal heart and in myocardial infarction. Ann N Y Acad Sci. 1990;593:148-160.
102. Riches DWH, Macrophage involvement in wound repair, remodeling, and fibrosis. In: Clark RAF, ed. The Molecular and Cellular Biology of Wound Repair. 2nd ed. New York, NY: Plenum Press; 1996:95-141.
103. Zhang G, Moorhead PJ, el Nahas AM. Myofibroblasts and the progression of experimental glomerulonephritis. Exp Nephrol. 1995;3:308-318.
104. Singer II, Kawka DW, Kazazis DM, Clark RAF. In vivo codistribution of fibronectin and actin fibers in granulation tissue: immunofluorescence and electron microscope studies of the fibronexus at the myofibroblast surface, J Cell Biol. 1984;98:2091-2106.
105. Bishop J, Greenbaum J, Gibson D, Yacoub M, Laurent GJ, Enhanced deposition of predominantly type I collagen in myocardial disease. J Mol Cell Cardiol, 1990;22:1157-1165.
106. Mukherjee D, Sen S. Collagen phenotypes during development and regression of myocardial hypertrophy in spontaneously hypertensive rats. Circ Res. 1990;67:1474-1480.
107. Weber KT, Janicki JS, Shroff SG, Pick R, Chen RM, Bashey RI. Collagen remodeling of the pressure-overloaded, hypertrophied nonhutnan primate myocardium. Circ Res. 1988;62:757-765.
108. Darby I, Skalli O, Gabbiani G. α-Smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing. Lab Invest. 1990:63:21-29.
109. Desmoulière A, Redard M, Darby I, Gabbiani G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol. 1995;146:56-66.
110. Bellamy COC, Malcomson RDG, Harrison DJ, Wyllie AH. Cell death in health and disease: the biology and regulation of apoptosis. Semin Cancer Biol. 1995;6:3-16.
111. Border WA, Ruoslahti E, Transforming growth factor-β in disease: the dark side of tissue repair. J Clin Invest. 1992;90:1-7.
112. Lawrence WT, Diegelmann RF, Growth factors in wound healing. Clin Dermatol. 1994;12:157-169.
113. 1 and extracellular matrix gene expression in isoprenaline induced cardiac hypertrophy: effects of inhibition of the renin-angiotensin system. Cardiovasc Res. 1994;28:1835-1842.
114. Chua CC, Chua BHL, Zhao ZY, Krebs C, Diglio C, Perrin E. Effect of growth factors on collagen metabolism in cultured human heart fibroblasts. Connect Tissue Res. 1991;26:271-281.
115. 1 receptor subtype. Circ Res. 1993;73:413-423.
116. 1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol. 1997;29:1947-1958.
117. Everett AD, Tufro-McReddie A, Fisher A, Gomez RA. Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-β1 expression. Hypertension. 1994;23:587-592.
118. Hinglais N, Heudes D, Nicoletti A, Mandet C, Laurent M, Bariéty J, Michel J-B. Colocalization of myocardial fibrosis and inflammatory cells in rats. Lab Invest. 1994;70:286-294.
119. Wardle N. Glomerulosclerosis: the final pathway is clarified, but can we deal with the triggers? Nephron. 1996;73:1-7.
120. Pimentel JL Jr, Martinez-Maldonado M, Wilcox JN, Wang S, Luo C. Regulation of renin-angiotensin system in unilateral ureteral obstruction. Kidney Int. 1993;44:390-400.
121. Sun Y, Ratajska A, Zhou G, Weber KT. Angiotensin converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone. J Lab Clin Med. 1993;122:395-403.
122. Sun Y, Weber KT. Angiotensin II and aldosterone receptor binding in rat heart and kidney: response to chronic angiotensin II or aldosterone administration. J Lab Clin Med. 1993;122:404-411.
123. Sun Y, Ratajska A, Weber KT. Inhibition of angiotensin converting enzyme and attenuation of myocardial fibrosis by lisinopril in rats receiving angiotensin II. J Lab Clin Med. 1995;126:95-101.
124. Sun Y, Ratajska A, Weber KT. Bradykinin receptor and tissue ACE binding in myocardial fibrosis: response to chronic angiotensin II or aldosterone administration in rats. J Mol Cell Cardiol. 1995;27:813-822.
125. Sun Y, Diaz-Arias AA, Weber KT. Angiotensin-converting enzyme, bradykinin and angiotensin II receptor binding in rat skin, tendon and heart valves: an in vitro quantitative autoradiographic study. J Lab Clin Med. 1994;123:372-377.
126. Allen AM, Yamada H, Mendelsohn FAO. In vitro autoradiographic localization of binding to angiotensin receptors in the rat heart. Int J Cardiol. 1990;28:25-33.
127. Yamada H, Fabris B, Allen AM, Jackson B, Johnston CI, Mendelsohn FAO. Localization of angiotensin converting enzyme in rat heart. Circ Res. 1991;68:141-149.
128. Pinto JE, Viglione P, Saavedra JM. Autoradiographic localization and quantification of rat heart angiotensin converting enzyme. Am J Hypertens. 1991;4:321-326.
129. Danilov SM, Faerman AI, Printseva OY, Martynov AV, Sakharov IY, Trakht IN. Immunohistochemical study of angiotensinconverting enzyme in human tissues using monoclonal antibodies. Histochemistry. 1987;87:487-490.
130. Katwa LC, Ratajska A, Cleutjens JPM, Sun Y, Zhou G, Lee SJ, Weber KT. Angioteitsin converting enzyme and kininase-II-Iike activities in cultured valvular interstitial cells of the rat heart. Cardiovasc. Res. 1995;29:57-64.
131. Nakajima Y, Miyazono K, Kato M, Takase M, Yamagishi T, Nakamura H. Extracellular fibrillat structure of latent TGFβ binding protein-1: role in TGPβ-dependent endothelialmesenchymal transformation during endocardial cushion tissue formation in mouse embryonic heart, J Cell Biol. 1997;136:193-204.
132. Potts JD, Vincent EB, Runyan RB, Weeks DL. Sense and antisense TGFβ mRNA levels correlate with cardiac valve induction. Dev Dyn. 1992;193:340-345.
133. Katwa LC, Tyagi SC, Campbell SE, Lee SJ, Cicila GT, Weber KT. Valvular interstitial cells express angiotensinogen, cathepsin D, and generate angiotensin peptides, Int J Biochem Cell Biol. 1996;28:807-821.
134. Weber KT, Sun Y, Katwa LC. Myofibroblasts and local angiotensin II in rat cardiac tissue repair. Int J Biochem Cell Biol. 1997;29:31-42.
135. Sun Y, Weber KT. Angiotensin II receptor binding following myocardial infarction in the rat. Cardiovasc Res. 1994;28:1623-1628.
136. Filip DA, Radu A, Simionescu M. Interstitial cells of the heart valves possess characteristics similar to smooth muscle cells. Circ Res. 1986;59:310-320.
137. Sims DE. The pericyte: a review. Tissue Cell. 1986;18:153-174.
138. Michel J-B, Lattion A-L, Salzmann J-L, Cerol ML, Philippe M. Camilleri J-P, Corvol P. Hormonal and cardiac effects of converting enzyme inhibition in rat myocardial infarction, Circ Res. 1988;62:641-650.
139. Yamagishi H, Kim S, Nishikimi T, Takeuchi K, Takeda T. Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats. J Mol Cell Cordial. 1993;25:1369-1380.
140. Pinto YM, de Smet BG, van Gilst WH, Scholtens E, Monnink S, de Graeff PA, Wesseling H. Selective and time related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphology, Cardiovasc Res. 1993;27:1933-1938.
141. Hodsman GP, Kohzuki M, Howes LG, Sumithran E, Tsunoda K, Johnston CI. Neurohumoral responses to chronic myocardial infarction in rats. Circulation. 1988;78:376-381.
142. Falkenhahn M, Franke F, Bohle RM, Zhu YC, Stauss HM, Bachmann S, Danilov S, Unger T, Cellular distribution of angiotensin-converting enzyme after myocardial infarction. Hypertension. 1995;25:219-226.
143. Benjamin IJ, Jalil JE, Tan LB, Cho K, Weber KT, Clark WA. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res. 1989;65:657-670.
144. Sun Y, Weber KT. Angiotensin-converting enzyme and wound healing in diverse tissues of the rat, J Lab Clin Med. 1996;127:94-101.
145. Lefroy DC, Wharton J, Crake T, Knock GA, Rutherford RAD, Suzuki T, Morgan K, Polak JM, Poole-Wilson PA. Regional changes in angiotensin II receptor density after experimental myocardial infarction. J Mol Cell Cardiol. 1996;28:429-440.
146. Sechi LA, Griffin CA, Grady EF, Kalinyak JE, Schambelan M. Characterization of angiotensin II receptor subtypes in rat heart. Circ Res. 1992;71:1482-1489.
147. Regitz-Zagrosek V, Friedel N, Heymann A, Bauer P, Neuβ M, Rolfs A, Steffan C, Hildebrandt A, Hetzer R, Fleck E. Regulation, chamber localization, and subtype distribution of angiotensin II receptors in hearts. Circulation. 1995;91:1461-1471.
148. Sun Y, Weber KT. Cells expressing angiotensin II receptors in fibrous tissue of rat heart. Cardiovasc Res. 1996;31:518-525.
149. Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction, J Clin Invest. 1995;95:46-54.
150. Makino N, Hata T, Sugano M, Dixon IMC, Yanaga T, Regression of hypertrophy after myocardial infarction is produced by the chronic blockade of angiotensin type I receptor in rats. J Mol Cell Cardiol. 1996;28:507-517.
151. Kimura B, Sumners C, Phillips MI, Changes in skin angiotensin II receptors in rats during wound healing. Biochem Biophys Res Commun. 1992;187:1083-1090.
152. Phillips MI, Kimura B, Gyurko R. Angiotensin receptor stimulation of transforming growth factor-β in rat skin and wound healing. In: Saavedra JM, Pieter BMWM, eds. Angiotensin Receptors. New York, NY: Plenum Press; 1994:377-396.
153. Viswanathan M, Saavedra JM. Expression of angiotensin II AT2 receptors in the rat skin during experimental wound healing. Peptides. 1992;13:783-786.
154. Schunkert H, Ingelfinger JR, Hirsch AT, Pinto Y, Remme WJ, Jacob H, Dzau VJ. Feedback regulation of angiotensin converting enzyme activity and mRNA levels by angiotensin II, Circ Res. 1993;72:312-318.
155. Alien RKA, Chai SY, Dunbar MS, Mendelsohn FAO. In vitro autoradiographic localization of angiotensin-converting enzyme in sarcoid lymph nodes. Chest. 1986;90:315-320.
156. Wickline SA, Verdonk ED, Wong AK, Shepard RK, Miller JG. Structural remodeling of human myocardial tissue after infarction: quantification with ultrasonic backscatter. Circulation. 1992;85:259-268.
157. Campbell DJ, Habener JF. Cellular localization of angiotensinogen gene expression in brown adipose tissue and mesentery: quantification of messenger ribonucleic acid abundance using hybridization in situ. Endocrinology.. 1987;121:1616-1626.
158. Cassis LA, Lynch KR, Peach MJ. Localization of angiotensinogen messenger RNA in rat aorta. Circ Res. 1988;62:1259-1262.
159. Sawa H, Tokuchi F, Mochizuki N, Endo Y, Furuta Y, Shinohara T, Takada A, Kawaguchi H, Yasuda H, Nagashima K. Expression of the angiotensinogen gene and localization of its protein in the human heart. Circulation. 1992;86:138-146.
160. Dostal DE, Rothblum KM, Chernin MI, Cooper GR, Baker KM. Intracardiac detection of angiotensinogen and renin: a localized renin-angiotensin system in neonatal rat heart. Am J Physiol. 1992;263:C838-C850.
161. Dostal DE, Rothblum KN, Conrad KM, Cooper GR, Baker KM. Detection of angiotensin I and II in cultured rat cardiac myocytes and fibroblasts. Am J Physiol. 1992;263:C851-C863.
162. von Lutterotti N, Catanzaro DF, Sealey JE, Laragh JH. Renin is not synthesized by cardiac and extrarenal vascular tissues; a review of experimental evidence. Circulation. 1994;89:458-470.
163. Danser AHJ, Honing MMG, Admiraal PJJ, Sassen LMA, Derkx. FHM, Verdouw PD, Schalekamp MADH. Production of angiotensins I and II at tissue sites in intact pigs. Am J Physiol. 1992;263:H429-H437.
164. Danser AHJ, Koning MMG, Admiraal PJJ. Derkx FHM, Verdouw PD, Schalekamp MADH. Metabolism of angiotensin I by different tissues in the intact animal. Am J Physiol. 1992;263:H418-H428.
165. Danser AHJ, van Kafz JP, Admiraal PJJ, Derkx FHM, Lamers JMJ, Verdouw PD, Saxena PR, Schalekamp MADH. Cardiac renin and angiotensins: uptake from plasma versus in situ synthesis. Hypertension. 1994;24:37-48.
166. Campbell DJ, Kladis A, Duncan AM. Nephrectomy, converting enzyme inhibition, and angiotensin peptides. Hypertension. 1993;22:513-522.
167. Wintroub BU, Klickstein LB, Dzau VJ, Watt KWK. Granulocyteangiotensin system: identification of angiotensinogen as the plasma protein substrate of leukocyte cathepsin G. Biochemistry. 1984;23:227-232.
168. Katwa LC, Campbell SE, Tyagi SC, Lee SJ, Cicila GT, Weber KT. Cultured myofibroblasts generate angiotensin peptides de novo. J Mol. Cell Cardiol. 1997;29:1375-1386.
169. Passier RCJJ, Smits JFM, Verluyten MJA, Studer R, Drexler H, Daemen MJAP. Activation of angiotensin-converting enzyme expression in infarct zone following myocardial infarction. Am J Physiol. 1995;269:H1268-H1276.
170. Iwai N, Inagami T, Ohmichi N, Kinoshita M. Renin is expressed in rat macrophage/monocyte cells. Hypertension. 1996;27:399-403.
171. Zhang X, Dostal DE, Reiss K, Cheng W, Kajstura J, Li P, Huang H, Sonnenblick EH, Meggs LG, Baker LM, Anversa P. Identification and activation of autocrine renin-angiotensin system in adult ventricular myocytes. Am J Physiol. 1995;269:H1791-H1802.
172. Keeley FW, Elmoselhi A, Leenen FHH. Enalapril suppresses normal accumulation of elastin and collagen in cardiovascular tissues of growing rats. Am J Physiol. 1992;262:H1013-H1021.
173. Albaladejo P, Bouaziz H, Duriez M, Gohlke P, Levy BI, Safar ME, Benetos A. Angiotensin converting enzyme inhibition prevents the increase in aortic collagen in rats. Hypertension. 1994;23:74-82.
174. Jugdutt BI, Khan MI, Jugdutt SJ, Blinston GE. Effect of enalapril on ventricular remodeling and function during healing after anterior myocardial infarction in the dog. Circulation. 1995;91:802-812.
175. Jugdutt BI, Schwarz-Michorowski BL, Khan MI. Effect of long-term captopril therapy on left ventricular remodeling and function during healing of canine myocardial infarction. J Am Coll Cardiol, 1992;19:713-721.
176. Jugdutt BI. Effect of captopril and enalapril on left ventricular geometry, function and collagen during healing after anterior and inferior myocardial infarction in a dog model. J Am Coll Cardiol. 1995;25:1718-1725.
177. Needleman P, Marshall GR, Sobel BE. Hormone interactions in the isolated rabbit heart: synthesis and coronary vasomotor effects of prostaglandins, angiotensin, and bradykinin. Circ Res. 1975;37:802-308.
178. Frimm C de C, Sun Y, Weber KT. Wound healing following myocardial infarction in the rat: role for bradykinin and prostaglandins. J Mol Cell Cardiol. 1996;28:1279-1285.
179. Frimm C de C, Sun Y, Weber KT. Angiotensin II receptor blockade and myocardial fibrosis of the infarcted rat heart. J Lab Clin Med. 1997;129:439-446.
180. Makino N, Matsui H, Masutomo K, Hata T, Yanaga T. Effect of angiotensin converting enzyme inhibitor on regression in cardiac hypertrophy. Mol Cell Biochem. 1993;119:23-28.
181. Bélichard P, Savard P, Cardinal R, Nadeau R, Gosselin H, Paradis P, Rouleau JL, Markedly different effects on ventricular remodeling result in a decrease in inducibility of ventricular arrhythmias. J Am Coll Cardiol. 1994;23:505-513.
182. Farivar RS, Crawford DC, Chobanian AV, Brecher P, Effect of angiotensin II blockade on the fibroproliferative response to phenylephrine in the rat heart. Hypertension. 1995;25(pt 2):II-809-II-813.
183. Pimentel JL Jr, Sundell CL, Wang S, Kopp JB, Montero A, Martinez-Maldonado M. Role of aogiotensin II in the expression and regulation of transforming growth factor-β in obstructive nephropathy. Kidney Int. 1995;48:1233-1246.
184. Morrissey JJ, Ishidoya S, McCracken R, Klahr S. The effect of ACE inhibitors on the expression of matrix genes and the role of p53 and p21 (WAF1) in experimental renal fibrosis. Kidney Int. 1996;49(suppl 54):S83-S87.
185. Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S. Angiotensin II receptor antagonist ameliorates renal tubulointerstital fibrosis caused by unilateral ureteral obstruction. Kidney Int. 1995;47:1285-1294.
186. Kaneto H, Morrissey J, McCracken R, Reyes A, Klahr S. Enalapril reduces collagen type IV synthesis and expansion of the interstitum in the obstructed rat kidney. Kidney Int. 1994;45:1637-1647.
187. Ishidoya S, Morrissey J, McCracken R, Klahr S. Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats with obstructive nephropathy. Kidney Int. 1996;49:1110-1119.
188. Yanagisawa H, Morrissey J, Morrison AR, Klahr S. Eicosanoid production by isolated glomeruli of rats with unilateral ureteral obstruction. Kidney Int. 1990;37:1528-1535.
189. Diamond JR, Anderson S. Irreversible tubulointerstitial damage associated with chronic aminonucleoside nephrosis. Am J Pathol. 1990;137:B23-1332.
190. Lafayette RA, Mayer G, Meyer TW. The effects of blood pressure reduction on cyclosporine nephrotoxicity in the rat. J Am Soc Nephrol. 1993;3:1892-1899.
191. Cohen EP, Moulder JE, Fish BL, Hill P. Prophylaxis of experimental bone marrow transplant nephropathy. J Lab Clin Med. 1994;124:371-380.
192. Tanaka R, Sugihara K, Tatematsu A, Fogo A. Internephron heterogeneity of growth factors and sclerosis: modulation of platelet-derived growth factor by angiotensin II. Kidney Int. 1995;47:131-139.
193. Ikoma M, Kawamura T, Kakinuma Y, Fogo A, Ichikawa I. Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int. 1991;40:195-202.
194. Shibouta Y, Chatani F, Ishimura Y, Sanada T, Ohta M, Inada Y, Nishikawa K. TCV-116 inhibits renal interstitial and glomerular injury in glomerulosclerotic rats. Kidney Int. 1996;49(suppl 55): S115-S118.
195. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 1986;77:1993-2000.
196. Juncos LI, Carrasco Dueñas S, Coroejo JC, Broglia CA, Cejas H. Long-term enalapril and hydrochlorothiazide in radiation nephritis. Nephron. 1993;64:249-255.
197. Nakamura T, Honma H, Ikeda Y, Kuroyanagi R, Takano H, Obata J, Sato T, Kimura H, Yoshida Y, Tamura K. Renal protective effects of angiotensin II receptor I antagonist CV-11974 in spontaneously hypertensive stroke-prone rats (SHR-sp). Blood Press. 1994;3(suppl 5):61-66.
198. Nakamura T, Obata J, Kuroyanagi R, Kimura H, Ikeda Y, Takano H, Naito A, Sato T, Yoshida Y. Involvement of angiotensin II in glomerulosclerosis of stroke-prone spontaneously hypertensive rats. Kidney Int. 1996;49(suppl 55):S109-S112.
199. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F, Iwao H. Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury. Kidney Int. 1994;46:1346-1358.
200. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Ishimura Y, Chatani F, Iwao H. Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-βl and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J Pharmacol Exp Ther. 1995;273:509-515.
201. Ward WF, Molteni A, Ts'ao C. Radiation-induced endothelial dysfunction and fibrosis in rat lung: modification by the angiotensin converting enzyme inhibitor CL242817. Radiat Res. 1989;117:342-350.
202. Ward WF, Molteni A, Ts'ao C, Kim YT, Hinz JM. Radiation pneumotoxicity in rats: modification by inhibitors of angiotensin converting enzyme. Int J Radial Oncol Biol Phys. 1992;22:623-625.
203. Ward WF, Molteni A, Ts'ao C-H, Hinz JM. Captopril reduces collagen and mast cell accumulation in irradiated rat lung. Int J Radiat Oncol Biol Phys. 1990;19:1405-1409.
204. Molteni A, Ward WF, Ts'ao C, Soliday NH, Dunnes M. Monocrotaline-induced pulmonary fibrosis in rats: amelioration by captopril and penicillamine. Proc Soc Exp Biol Med. 1985;180:112-120.
205. Sun Y, Ramires FJA, Zhou G, Ganjam VK, Weber KT. Fibrous tissue and angiotensin II. J Mol Cell Cardiol. 1997;29:2001-2012.
206. Weber KT. Fibrosis: a common pathway to organ failure: angiotensin II and tissue repair. Semin Nephrol. 1997;17:467-491.
207. Villarreal FJ, Kim NN, Ungab GD, Printz MP, Dillmann WH. Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation. 1993;88:2849-2861.
208. Brilia CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone, J Mol Cell Cardiol. 1994;26:809-820.
209. Zhou G, Kandala JC, Tyagi SC, Katwa LC, Weber KT. Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts. Mol Cell Biochem. 1996;154:171-178.
210. Lee AA, Dillmann WH, McCulloch AD, Villarreal FJ. Angiotensin II stimulates the autocrine production of transforming growth factor-βl in adult rat cardiac fibroblasts. J Mol Cell Cardiol. 1995;27:2347-2357.
211. Tufro-McReddie A, Chevalier RL, Everett AD, Gomez RA. Decreased perfusion pressure modulates renin and ANG II type 1 receptor gene expression in the rat kidney. Am J Physiol. 1993;264:R696-R702.
212. 2-receptor subtypes in hypertrophied rat hearts. Am J Physiol. 1994;267:H844-H852.
213. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res. 1990;67:1355-1364.
214. Chapman D, Weber KT, Eghbali M. Regulation of fibrillar collagen types I and III and basement membrane type IV collagen gene expression in pressure overloaded rat myocardium. Circ Res. 1990;67:787-794.
215. Willems IEMG, Havenith MG, Smits JFM, Daemon MJAP. Structural alterations in heart valves during left ventricular pressure overload in the rat. Lab Invest, 1994;71:127-133.
216. Goldblatt H. Experimental hypertension induced by renal ischemia (Harvey Lecture). Bull N Y Acad Med. 1938;14:523-553.
217. Selye H. The general adaptation syndrome and the diseases of adaptation. J Clin Endocrinol. 1946;6:117-230.
218. Hall CE, Hall O. Hypertension and hypersalimentation, I: aldosterone hypertension. Lab Invest. 1965;14:285-294.
219. Nicoletti A, Mandet C, Challah M, Bariéty J, Michel J-B. Mediators of perivascular inflammation in the left ventricle of renovascular hypertensive rats. Cardiovasc Res. 1996;31:585-595.
220. Jalil JE, Janicki JS, Pick R, Weber KT. Coronary vascular remodeling and myocardial fibrosis in the rat with renovascular hypertension: response to captopril. Am J Hypertens. 1991;4:51-55.
221. Nicoletti A, Heudes D, Hinglais N, Appay M-D, Philippe M, Sassy-Prigent C, Bariety J, Michel J-B. Left ventricular fibrosis in renovascular hypertensive rats: effect of losartan and spironolactone. Hypertension. 1995;26:101-111.
222. Regan CP, Andersen PG, Bishop SP, Berecek KH. Captopril prevents vascular and fibrotic changes but not cardiac hypertrophy in aortic-banded rats. Am J Physiol. 1996;271:H906-H913.
223. Linz W, Schaper J, Wiemer G, Albus U, Schölkens BA. Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats. Br J Pharmacol. 1992;107:970-975.
224. Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, Floege J, Schwarte SM. Renal injury from angiotensin II-mediated hypertension, Hypertension. 1992;19:464-474.
225. Crawford DC, Chobanian AV, Brecher P. Angiotensin II induces fibronectin expression associated with, cardiac fibrosis in the rat. Circ Res. 1994;74:727-739.
226. Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K, Iwao H. Aogiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension. 1995;25:1252-1259.
227. Weber KT, Sun Y, Guarda E. Nonclassic actions of angiotensin II and aldosterone in nonclassic target tissue (the heart): relevance to hypertensive heart disease. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management 2nd ed. New York, NY: Raven Press; 1995;2:2203-2223.
228. Weber KT. Hormones and fibrosis: a case for lost reciprocal regulation. News Physiol Sci. 1994;9:123-128.
229. Brenner DA, Rippe RA, Rhodes K, Trotter JF, Breindl M. Fibrogenesis and type I collagen gene regulation, J Lab Clin Med. 1994;124:755-760.
230. Appleton I, Tomlinson A, Chander CL, Willoughby DA, Effect of enclothelin-l on croton oil-induced granulation tissue in the rat: a pharmacologic and immunohistochemical study. Lab Invest. 1992;67:703-710.
231. Zeballos GA, An SJ, Wu JM. Endothelin-1 secretion by human fibroblasts in culture: effects of cell density and IFN-β. Biochem Int. 1991;25:845-852.
232. Firth JD, Schricker K, Ratcliffe PJ, Kurtz A. Expression of endothelins 1 and 3 in the rat kidney. Am J Physiol. 1995;269:F522-F528.
233. Ikeda M, Kohno M, Takeda T. Endothelin production in cultured mesangial cells of spontaneously hypertensive rats. Hypertension. 1995;25:1196-1201.
234. Bakris GL, Re RN. Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells. Am J Physiol. 1993;264:F937-F942.
235. Guarda E, Katwa LC, Myers PR, Tyagi SC, Weber KT. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res. 1993;27:2130-2134.
236. Katwa LC, Guarda E, Weber KT. Endothelin receptors in cultured adult rat cardiac fibroblasts, Cardiovasc Res. 1993;27:2125-2129.
237. Schrey MP, Patel KV, Tezapsidis N. Bombesin and glucocorticoids stimulate human breast career cells to produce endothelin, a paracrine mitogen for breast stromal cells. Cancer Res. 1992;52:1786-1790.
238. Karam H, Heudes D, Hess P, Gonzales MF, Loffler BM, Clozel M, Clozel JP. Respective role of humoral factors and blood pressure in cardiac remodeling of DOCA hypertensive rats. Cardiovasc Res. 1996;31:287-295.
239. Benigni A, Zoja C, Corna D, Orisio S, Longaretti K, Bertani T, Remuzzi G, A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int. 1994;46:696-702.
240. Moncada S, Higgs EA. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J. 1995;9:1319-1330.
241. Lyons CR. The role of nitric oxide in inflammation. Adv Immunol. 1995;60:323-371.
242. Nathan C, Xie Q. Regulation of biosynthesis of nitric oxide. J Biol Chem. 1994;269:13725-13728.
243. 2+M phase. FEES Lett. 1994;340:159-162.
244. Sigusch HH, Campbell SE, Weber KT. Angiotensin II-induced myocardial fibrosis in rats: role of nitric oxide, prostaglandins and bradykinin. Cardiovasc Res. 1996;31:546-554.
245. Hou J, Kato H, Cohen RA, Chobanian AV, Brecher P. Angiotensin II-induced cardiac fibrosis in the rat is increased by chronic inhibition of nitric oxide synthase, J Clin Invest. 1996;96:2469-2477.
246. Numaguchi K, Egashira K, Takemoto M, Kadokami T, Shimokawa H, Sueishi K, Takeshita A. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension. 1995;26:957-962.
247. Takemoto M, Egashira K, Usui M, Numaguchi K, Tomita H, Tsutsui H, Shimokawa H, Sueishi K, Takeshita A. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest. 1997;99:278-287.
248. Regoli D, Barabé J. Pharmacology of bradykinin and related kinins. Pharmacol Rev. 1980;32:1-46.
249. Evens AS, Murphree S, Safftz JE, Jakschik BA, Needleman P. Effects of endogenously produced leukotrienes, thromboxane, and prostaglandins on coronary vascular resistance in rabbit myocardial infarction. J Clin Invest. 1985;75:992-999.
250. 2) and 12L-hydroxy-5,8,10,14-eicosatetracnoic acid (HETE) by pericardium, pleura, peritoneum and aorta of the rabbit. Prostaglandins. 1979;18:439-452.
251. Satoh K, Prescott SM. Culture of mesothelial cells from bovine pericardium and characterization of their arachidonate metabolism, Biochim Biophys Acta. 1980;930:283-296.
252. Bareis DL, Manganiello VC, Hirata F, Vaughan M, Axelrod J. Bradykinin stimulates phospholipid methylation, calcium influx, prostaglandin formation, and cAMP accumulation in human fibroblasts. Proc Natl Acad Sci USA. 1983;80:2514-2518.
253. 2 synthesis: persistence of an abnormal phenotype after short-term exposure to mononuclear cell products. J Clin Invest. 1983;71:1240-1246.
254. Weber DR, Stroud ED, Prescott SM, Arachidonate metabolism in cultured fibroblasts derived from normal and infarcted canine heart. Circ Res. 1989;65:671-683.
255. Lindpaintner K, Lu W, Niedermajer J, Schiefer B, Just H, Ganten D, Drexler H, Selective activation of cardiac angiotensinogen gene expression in post-infarction ventricular remodeling in the rat, J Mol Cell Cardiol. 1993;25:133-143.
256. McCluskey ER, Corr PB, Lee BI, Saffitz JE. Needleman P. The arachinodic acid metabolic capacity of canine: myocardium is increased during healing of acute myocardial infarction. Circ Res. 1982;51:743-750.
257. Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, Willoughby DA. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci U S A. 1994;91:2046-2050.
258. Stuehr DJ, Nathan CF. Nitric oxide: a macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med. 1989;169:1543-1555.
259. Albina JE, Cui S, Mateo RB, Reichner JS. Nitric oxide-mediated apoptosis in murine peritoneal macrophages, J Immunol 1993;150:5080-5085.
260. Silverstein E, Friedland J, Vuletin JC. Marked elevation of serum angiotensin-converting enzyme and hepatic fibrosis containing long-spacing collagen fibrils in type 2 acute neuronopathic Gaucher's disease. Am J Clin Pathol. 1978;69:467-471.
261. Chua CC, Hamdy RC, Chua BHL. Angiotensin II induces TIMP-1 production in rat heart endothelial cells. Biochim Biophys Acta. 1996;1311:175-180.
262. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular aldosterone: biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem. 1994;269:24316-24320.
263. Takeda Y, Miyamori I, Yoneda T, Iki K, Hatakeyama H, Blair IA, Hsieh F-Y, Takeda R. Synthesis of corticosterone in the vascular wall. Endocrinology. 1994;135:2283-2286.
264. Klauber N, Browne F, Anand-Apte B, D'Amato RJ. New activity of spironolactone: inhibition of angiogenesis in vitro and in vivo. Circulation. 1996;94:2566-2571.
265. Guntaka RV, Kovacs A, Kandala JC, Weber KT. Regulation of fibrillar collagen gene expression. In: Weber KT, ed. Wound Healing in Cardiovascular Disease. Armonk, NY: Futura; 1995:281-294.
266. Irle C, Kocher O, Gabbiani G, Contractility of myofibroblasts during experimental liver cirrhosis. J Submicrosc Cytol. 1980;12:209-217.
267. Evans JN, Kelley J, Low RB. Adler KB. Increased contractility of isolated lung parenchyma in an animal model of pulmonary fihrosis induced by bleomycin. Am Rev Respir Dis. 1982;125:89-94.
268. De Mey JGR, Fazzi GE. A smooth muscle-like component in rat myocardial infarcts. Hypertension. 1996;28:696. Abstract.
269. Kessler KM. Heart failure with normal systolic function: update of prevalence, differential diagnosis, prognosis, and therapy. Arch Intern. Med. 1988;148:2109-2111.
270. Pearlman ES, Weber KT, Janicki JS, Pietra G, Fishman AP. Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab Invest. 1982;46:158-164.
271. Huysman JAN, Vliegen HW, Van der Laarse A, Eulderink F. Changes in nonmyocyte tissue composition associated with pressure overload of hypertrophic human hearts. Pathol Res Pract. 1989;184:577-581.
272. Haber HL, Powers ER, Gimple LW, Wu CC, Subbiah K, Johnson WH, Feldman MD. Intracoronary angiotensin-converting enzyme inhibition improves diastolic function in patients with hypertensive left ventricular hypertrophy. Circulation. 1994;89:2616-2625.
273. Friedrich SP, Lorell BH, Rousseau MF, Hayashida W, Hess OM, Douglas PS, Gordon S, Keighley CS, Benedict C, Krayenbuehl HP, Grossman W, Pouleur H. Intracardiac angiotensin-converting enzyme inhibition improves diastole function in patients with left ventricular hypertrophy due to aortic stenosis. Circulation. 1994; 90:2761-2771.
274. Krayenbuehl HP, Hess OM, Schneider J, Turina M. Physiologic or pathologic hypertrophy. Eur Heart J. 1983;4:29-34.
275. Hess OM, Ritter M, Schneider J, Grimm J, Turina M, Krayenbuehl HP. Diastolic stiffness and myocardial structure in aortic valve disease before and after valve replacement. Circulation. 1934;69:855-865.
276. Villari B, Campbell SE, Hess OM, Mall G, Weber KT, Krayenbuehl HP. Influence of collagen network on left ventricular systolic and diastolic function in aortic valve disease. J Am Coll Cardiol. 1993;22:1477-1484.
277. Rousseau MF, Gurnè O, van Eyll C, Benedict CR, Pouleur H. Effects of benazeprilat on left ventricular systolic and diastolic function and neurohormonal status in patients with ischemic heart disease. Circulation. 1990;81(suppl III):III-123-III-129.